Publications by authors named "Luc-Matthieu Fornecker"

Claim this Profile
L
Large B-cell lymphoma: The LYSA pragmatic guidelines.
Pierre Sesques, Guillaume Manson, Sydney Dubois, Francois Xavier Gros, Gabriel Brisou, Luc Matthieu Fornecker

Eur J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials.
Valentin Letailleur, Isabelle Chaillol, Fanny Cherblanc, Hervé Ghesquières, Frédéric Peyrade, Luc-Matthieu Fornecker

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial intelligence-based flow cytometry for the diagnosis of B-cell chronic lymphoproliferative disorders.
Laurent Mauvieux, Raoul Herbrecht, Alice Eischen, Anne-Cécile Galoisy, Delphine Rolland, Luc-Matthieu Fornecker

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.
Gabriel Brisou, Jérôme Paillassa, Sophie Bernard, Olivier Tournilhac, Luc-Matthieu Fornecker

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-HLA class I IgG subclasses skew platelet activation mechanisms in transfusion refractoriness.
Adèle Couvidou, Mathieu Wald, Catherine Angénieux, Juliana Pires-Marafon, Marie-Joëlle Apithy, Luc-Matthieu Fornecker

Haematologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.
Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah, Stéphanie Guidez, Olivier Casasnovas, Luc-Matthieu Fornecker

Br J Haematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine.
Sylvain Lamure, Houria Hendel Chavez, Marie-Ghislaine de Goër de Herve, Luc-Matthieu Fornecker, Bernard Drenou

Front Immunol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma.
Vincent Camus, Thierry Molina, Fabienne Desmots, Paul Blanc-Durand, Salim Kanoun, Luc-Matthieu Fornecker

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.
Vincent Camus, Roch Houot, Gabriel Brisou, Benoit Tessoulin, Sébastien Bailly, Luc-Matthieu Fornecker

Blood Adv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Nurturing and growing a community of department heads: Act 2 in haematology].
Roch Houot, Claire Calmettes, Sophie Park, Laurent Pascal, Regis Peffault de Latour, Luc-Matthieu Fornecker

Bull Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.
Amélie Anota, Mathurine Basset, Emilie Charton, Côme Bommier, Fabio Efficace, Luc-Matthieu Fornecker

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Sylvain Carras, Alexia Torroja, Anouk Emadali, Emilie Montaut, Nicolas Daguindau, Luc Matthieu Fornecker

Haematologica· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
Jehan Dupuis, Emmanuel Bachy, Franck Morschhauser, Guillaume Cartron, Noriko Fukuhara, Luc-Matthieu Fornecker

Lancet Haematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.
Hervé Ghesquières, Fanny Cherblanc, Aurélien Belot, Sophie Micon, Krimo K Bouabdallah, Luc-Matthieu Fornecker

Blood Adv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.
Stefan K Alig, Mohammad Shahrokh Esfahani, Andrea Garofalo, Michael Yu Li, Cédric Rossi, Luc-Matthieu Fornecker

Nature· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Bruton's Tyrosine Kinase Gene Overexpression and Risk of Lymphoma in Primary Sjögren's Syndrome.
Pierre-Marie Duret, Cedric Schleiss, Lou Kawka, Nicolas Meyer, Tao Ye, Luc-Matthieu Fornecker

Arthritis Rheumatol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Creating a community of heads of department to meet hospital system challenges: First experience in haematology].
Roch Houot, Jacques-Olivier Bay, Patrice Chevallier, Sylvain Choquet, Luc-Matthieu Fornecker

Bull Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
Guillaume Cartron, Emmanuel Bachy, Hervé Tilly, Nicolas Daguindau, Gian-Matteo Pica, Luc-Matthieu Fornecker

J Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis of a cohort of 41 B-cell prolymphocytic leukemia patients: impact of genetics and targeted therapies (a FILO study).
Caroline Algrin, Louis Pérol, Elise Chapiro, Lucile Baseggio, Karim Maloum, Luc-Matthieu Fornecker

Haematologica· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 Infection in Patients With Waldenström's Macroglobulinemia: A Multicenter International Cohort Study.
Irene Defrancesco, Virginia Valeria Ferretti, Pierre Morel, Charalampia Kyriakou, Efstathios Kastritis, Luc Matthieu Fornecker

Hemasphere· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma.
Gwladys Claustre, Coralie Boulanger, Frédéric Maloisel, Nelly Etienne-Selloum, Luc-Matthieu Fornecker

J Cancer Res Clin Oncol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
Sammara Chaubard, Amira Marouf, David Lavergne, François Lemonnier, Julien Rossignol, Luc-Matthieu Fornecker

Br J Haematol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Luc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, René-Olivier Casasnovas, Anne-Claire Gac

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline.
Cédric Rossi, Marc André, Jehan Dupuis, Franck Morschhauser, Bertrand Joly, Luc-Matthieu Fornecker

Haematologica· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Short- and Long-Term Mortality in Patients with or without Cancer Admitted to the ICU for Septic Shock: A Retrospective Observational Study.
Pierrick Le Borgne, Léa Feuillassier, Maleka Schenck, Jean-Etienne Herbrecht, Ralf Janssen-Langenstein, Luc-Matthieu Fornecker

Cancers (Basel)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis